IL-17 Antibody Development Service

Interleukin-17 (IL-17) antibodies have been preliminary used in the therapeutics of autoimmune diseases with variant therapeutic effects. Our company provides cutting-edge research services to help you develop highly specific antibodies and accelerate the therapeutic antibodies development in Autoimmune Diseases & Inflammation.

IL-17 in Autoimmune Diseases & Inflammation

IL-17, refer as IL-17A, is a pro-inflammatory cytokine belonging to a family that also includes five other members (IL-17B to IL-17F). IL-17 is released by distinct kinds of adaptive and innate immune cells, predominantly the Th17 cells, that response to the stimulation with IL-1β and IL-23. Afterwards, a series of inflammatory mediators, cytokines and signaling pathways are activated in different cell populations to regulate the balance of immune system. Elevated IL-17 levels accompanied with dysregulated production of Th17 cells are considered as a hallmark in the development and progression of autoimmune diseases. IL-17 and its closely related factors have attracted much attention as the therapeutic targets for mediating immunopathology in autoimmune diseases.

Fig.1 Aberrant T cell signaling and interleukin (IL)-17 production in systemic lupus erythematosus pathogenesis  (Koga T., et al., 2021)

• IL-17 in Psoriasis
  Increased level of IL-23 induces IL-17A and IL-17F production from immune cells including γδT cells, CD8+ T cells (Tc17 and Tc22) and innate lymphoid cells. IL-36α in Langerhans cells evoke chemokines and cytokines to induce the production of IL-17A, IL-17F and IL-22, subsequently facilitating the generation of inflammatory factors from keratinocytes and fibroblasts. Thus all of the cytokines form an amplified loop to activate cells in immune system to aggravate the inflammation.

• IL-17 in Systemic Lupus Erythematosus
  The elevated level of IL-17 levels and the increased frequency of IL-17-producing cells are highly possible to be a hallmark of systemic lupus erythematosus (SLE) pathogenesis. IL-17 recruits neutrophils, a crucial type of cells in SLE, to target tissues to promote inflammatory response and cell death. Additionally, IL-17 induces the production of IL-6 from B cells and then both cytokines work together accelerate the differentiation of B cells. Therefore, IL-17 plays multiple roles in inflammation in the development of SLE.

• IL-17 in Multiple Sclerosis
  Autoreaction of immune cells and elevated production of cytokines, including IL-6, IL-18 and IL-23, promote the differentiation of Th17 cells. Then Th17 cells induce inflammatory cytokines, resulting in the neurologic dysfunction. Expanded number of IL-17-expressing cells in the lesions of central nervous system is a typical symptom of multiple sclerosis (MS), as exemplified by the disruption of tight junction at blood brain barrier caused by high levels of IL-17 and IL-17R in the endothelial cells.

Our Services

IL-17 and its associated factors are involved in a variety of cytopathic effects in Autoimmune Diseases & Inflammation, and the inhibition of these proteins by therapeutic antibodies is one of the promising therapeutic modalities. Our company provides thorough package of antibodies development services for IL-17 signaling pathways as the following workflow: 

Antigen Validation

IL-17 signaling pathways

Antibody Generation

Antibody Optimization

Antibody Characterization

Antibody Production & Purification

Our advantages

With the involvement of specialized cellular immunology researchers and extensive experience in antibody development, our company is committed to providing meticulous services for the development of therapeutic antibodies to IL-17 signaling pathways. If you are interested in our services, please contact us for more detailed information.

Reference

1. Koga, Tomohiro et al. "Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus." Frontiers in immunology 11 (2021) 624971.